The size of the In-Vitro diagnostics market in the Middle East & Africa has been estimated at USD 7 billion in 2019 and is expected to reach 10.23 billion in 2024 at a Compound Annual Growth Rate (CAGR) of 6.17%.
The rise in the number of people suffering from cancer and diabetes is straightly leveling up the demand of the market. In the Middle East and Africa, government authorities are taking initial steps to improve healthcare services with IVD products and this is enhancing the growth rate of this market. In addition, these devices are accurate and convenient to perform diagnostics tests which are propelling the demand of the in-vitro diagnostics market in the Middle East and Africa. The increasing scale of diagnostics centers and hospitals across the region is also leveling up the growth rate of the market.
However, people in rural areas are less aware of these diagnostic procedures where it is declining the growth rate of the in-vitro diagnostics market in the Middle East and Africa. Lack of reimbursement schemes by the government in undeveloped countries is hindering the demand of the market. The major challenging factor for the market developers is strict rules and regulations by the government in approving various IVD products. Frequent changes in the economic strategies may also impact negatively the growth rate of the market in the Middle East and Africa. The dearth of skilled people in monitoring the systems effectively due to less training programs is impeding the demand of the market.
Growing incidences of cancer, diabetes and cardiac problems among many individuals and their prevalence for effective treatment procedures is likely to bolster the demand of the market. Rising support from the public and private organizations in developing innovative products is creating growth opportunities for the market. Along with this, the prevalence of early diagnosis is straightly fuelling the growth rate of the in-vitro diagnostics market in the Middle East and Africa. Research and development institutes are focusing on launching innovative products with the latest technology in order to improve the quality of diagnostic and treatment procedures which is ascribed to boost up the demand of the market in this region.
This research report segmented and sub-segmented into the following categories:
Most promising companies in the market
Companies playing a crucial role in the MEA IVD Market are Abbott Laboratories, Johnson and Johnson, Siemens Healthcare, Becton Dickinson, Roche Diagnostic, Beckman Coulter Inc., Biomérieux, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation & Thermo Fisher Scientific, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Instruments
5.1.2 Reagents and Kits
5.1.3 Software
5.2 By Technology
5.2.1 Clinical Chemistry
5.2.2 Hematology
5.2.3 Immunoassays
5.2.4 Coagulation and Hemostasis
5.2.5 Molecular Diagnostics
5.2.6 Microbiology
5.2.7 Other IVD technologies
5.3 By Application
5.3.1 Diabetes
5.3.2 Infectious Diseases
5.3.3 Oncology/Cancer
5.3.4 Cardiology
5.3.5 Nephrology
5.3.6 Autoimmune Diseases
5.3.7 Drug Testing
5.3.8 HIV
6.1 Introduction
6.2 Middle-East
6.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Siemens Healthcare
8.4 Becton Dickinson
8.5 Roche Diagnostics
8.6 Beckman Coulter Inc.
8.7 Biomérieux
8.8 Ortho Clinical Diagnostics, Inc.
8.9 Bio-Rad Laboratories, Inc.
8.10 Danaher Corporation
8.11 Sysmex Corporation
8.12 Thermo Fisher Scientific, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Aug 2019
Download Sample
